Janssen Infectious Diseases-Diagnostics BVBA (Janssen) - Articles and news items

Janssen Pharmaceuticals Logo

Incivo®(Telaprevir) data to be presented at AASLD and ISPOR on the anit-viral response, safety, tolerability and cost-effectiveness of an Incivo based regimen in the treatment of genotype-1 chronic hepatitis C

Industry news / 1 November 2013 / Janssen

Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients…

Janssen Pharmaceuticals Logo

INCIVO® (telaprevir) receives European Commission approval

Industry news, News / 31 May 2013 / Daniel J Edelman Ltd

The EC has approved a new twice daily dosing of INCIVO® (telaprevir)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...